Teva Branded Pharmaceutical Products R&d, Inc.

This study tests whether fremanezumab, a monthly injection, can prevent episodic migraine in children aged 6 to 17. Participants receive either the drug or a placebo for 12 weeks, and researchers track changes in monthly migraine days. The goal is to see if fremanezumab is safe a…

This phase 2b trial tested a new drug called TEV-48574 (duvakitug) in 290 adults with moderate to severe ulcerative colitis or Crohn's disease. The study aimed to see if the drug could help patients achieve clinical remission (for UC) or an endoscopic response (for CD) after 14 w…

This study tested a digital system that includes a smart inhaler, a phone app, and a dashboard for doctors to help people with asthma better manage their condition. Over 12 weeks, 333 participants aged 13 and older used either the smart system or their usual rescue inhaler. The g…

This study tested a drug called fremanezumab, given as a shot under the skin, to prevent migraines in 365 Chinese adults. Participants received either monthly or quarterly injections or a placebo for 12 weeks, followed by an open-label period. The main goal was to see if the drug…

This study tested whether a monthly injection of fremanezumab can prevent chronic migraines in children aged 6 to 17. About 292 participants received either the drug or a placebo. The main goal was to see if the drug reduced the number of migraine days per month over 12 weeks. Th…